Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma
This study demonstrates that in Ras-mutant multiple myeloma, c-Myc protein stability serves as a key differentiator between resistance to MEK inhibition and universal sensitivity to direct Ras inhibition, suggesting that targeting Ras directly is a more effective therapeutic strategy than inhibiting the downstream MAPK pathway.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the human body, a single cell can sometimes lose its ability to know when to stop growing, turning into a cancer that spreads and resists treatment. One of the most common drivers of this runaway growth is a broken version of a protein called Ras. Normally, Ras acts like a switch that tells the cell to divide, but when it is mutated, the switch gets stuck in the "on" position, forcing the cell to multiply uncontrollably. This broken switch activates a chain of signals inside the cell, much like a line of falling dominoes, which eventually tells the cell to keep growing. Scientists have long tried to stop this process by blocking the proteins in the middle of that chain, hoping to stop the signal before it reaches the cell's growth center. However, in a specific type of blood cancer called multiple myeloma, these attempts have often failed, leaving doctors and patients searching for a better way to turn off the cancer.
Researchers at the National Cancer Institute recently set out to understand why some multiple myeloma cells with broken Ras switches respond to treatment while others do not. They focused on two different ways to stop the cancer: one drug that tries to block the broken Ras switch directly, and another that tries to stop the signal chain further down the line. The team tested these drugs on a variety of multiple myeloma cells taken from patients. They found that while all the cancer cells relied heavily on the broken Ras switch to survive, they reacted very differently to the drug that blocked the signal chain. Some cells stopped growing when the chain was blocked, but others ignored the drug completely and kept dividing. This difference was not because the drug failed to stop the signal; the drug successfully halted the chain in every cell. The difference lay in what happened to a specific growth protein called c-Myc after the signal was cut.
In the cells that responded well to the treatment, cutting the signal chain caused the c-Myc protein to fall apart quickly, leaving the cell without the fuel it needed to grow. But in the cells that resisted the treatment, the c-Myc protein remained stable and intact, even though the signal chain was broken. The researchers discovered that the stability of this c-Myc protein was the deciding factor. When they artificially made the c-Myc protein more stable in the sensitive cells, those cells suddenly became resistant to the treatment. Conversely, when they made the protein less stable, the cells became more vulnerable. This suggested that the cancer cells had found a way to protect their c-Myc protein from being destroyed, allowing them to keep growing even when the main signal was blocked.
The study then turned to the drug that targets the Ras switch directly. Unlike the other treatment, this drug reduced the levels of the c-Myc protein in every single cell line tested, regardless of whether the cells had previously been resistant to the signal-blocking drug. Even when the researchers tried to force the cells to make more c-Myc protein, the direct Ras drug still worked, and the cells could not overcome its effect. This indicates that while protecting the c-Myc protein can help cancer cells survive a blocked signal chain, it is not enough to protect them from a drug that attacks the broken switch at its source. The findings suggest that for patients with this type of cancer, targeting the broken Ras switch directly might be a more reliable strategy than trying to block the signals further down the line, as it bypasses the specific defense mechanism the cancer cells use to survive.
The researchers also looked at other potential reasons why some cells resisted the treatment, such as changes in other signaling pathways or different types of cell cycle proteins. They systematically tested these possibilities and found that none of them could explain the resistance. The only factor that consistently matched the behavior of the cells was the stability of the c-Myc protein. By using genetic tools to alter the protein's stability, they confirmed that this single change was enough to switch a cell from being sensitive to being resistant. This work provides a clear explanation for why previous treatments have had mixed results and points toward a more precise approach for future therapies. The study does not claim to have solved the problem of treating multiple myeloma, but it offers a concrete reason for the differences seen in patients and suggests that new drugs designed to hit the Ras switch directly could offer a more consistent path to stopping the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.